Sharekhan's research report on Divis Laboratories
Divis Laboratories Limited (Divis) is expected to benefit from strong growth in the global active pharmaceutical ingredients (API) space. Divis has identified new growth avenues, which include entry in the contrast media manufacturing and identification of next 10 molecules which have gone off patent. The new avenues could drive the company’s growth ahead. Divis strict adherence to IPR norms, proven delivery capability through the development cycle, commercial supply track record, backward integration and strong relationship with pharma majors are key advantages.
Outlook
We re-iterate Buy recommendation on the stock with an unchanged PT of Rs. 4,500.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More